781 reports of this reaction
5.6% of all AZELASTINE HYDROCHLORIDE reports
#1 most reported adverse reaction
TREATMENT FAILURE is the #1 most commonly reported adverse reaction for AZELASTINE HYDROCHLORIDE, manufactured by Alembic Pharmaceuticals Limited. There are 781 FDA adverse event reports linking AZELASTINE HYDROCHLORIDE to TREATMENT FAILURE. This represents approximately 5.6% of all 14,064 adverse event reports for this drug.
Patients taking AZELASTINE HYDROCHLORIDE who experience treatment failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TREATMENT FAILURE is moderately reported among AZELASTINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to treatment failure, the following adverse reactions have been reported for AZELASTINE HYDROCHLORIDE:
The following drugs have also been linked to treatment failure in FDA adverse event reports:
TREATMENT FAILURE has been reported as an adverse event in 781 FDA reports for AZELASTINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TREATMENT FAILURE accounts for approximately 5.6% of all adverse event reports for AZELASTINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience treatment failure while taking AZELASTINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.